Literature DB >> 26300513

Overhydration prevalence in peritoneal dialysis - A 2 year longitudinal analysis.

Pedro Ventura Aguiar1, Olívia Santos2, Laetitia Teixeira3, Fernanda Silva2, Pedro Azevedo2, Joana Vidinha4, Francisco Ferrer5, Maria João Carvalho6, António Cabrita2, Anabela Rodrigues6.   

Abstract

BACKGROUND AND OBJECTIVES: Hypervolemia is a major concern in dialysis patients, and is associated with increased cardiovascular risk and death. Cross sectional analysis have previously demonstrated that peritoneal dialysis (PD) patients are not more overhydrated when compared to haemodialysiś ones. This study was designed to evaluate longitudinal trends in hydration status and corporal composition in a PD population.
METHODS: We conducted a 2 year prospective observational study of 58 PD patients from a single centre. Incident and prevalent patients were included. Yearly measurements were performed using multifrequency electric bioimpedance. Overhydration (OH) was defined as an extra-cellular water (ECW)/total body water (TBW) over 15%. Clinical and biochemical variables were also explored.
RESULTS: A total of 30 patients completed evaluation (female 63.3%, mean age 56.9 years, BMI 25.0 kg/m², diabetes 10.0%, APD-50.0%). Median PD vintage was 21.9 months, and 36.7% were anuric. At baseline 6.7% were overhydrated. On longitudinal analysis no significant changes were found in hydration status, systolic blood pressure, pro-BNP, nor albumin levels. Similar results were found among incident (n=11; APD- 45.5%; anuric- 9.1%) and prevalent (n=19; APD- 52.6%; anuric- 52.6%) patients (p>.05). However, at the second year, prevalent patients were moderately overhydrated compared to incident ones (median 10.2% vs 3.5%; p=.009). Nonetheless, no statistical difference was observed considering adequacy, TBW, or ECW. Moreover, nutritional parameters remained stable.
CONCLUSIONS: Peritoneal dialysis maintenance without increasing volume status, nor major deleterious corporal composition trends, is feasible under careful therapy strategies. Longitudinal application of BIA may be a useful clinical tool to evaluate adequacy beyond Kt/V.
Copyright © 2015. Published by Elsevier España, S.L.U.

Entities:  

Keywords:  Bioimpedancia; Diálisis Peritoneal; Hipertensión; Hypertension; Multifrequency bioimpedance; Nutrición; Nutritional status; Overhydration; Peritoneal dialysis; Prescribed dialysis dose; Prescripción; Sobrehidratación; Volume status; Volumen

Mesh:

Year:  2015        PMID: 26300513     DOI: 10.1016/j.nefro.2015.05.020

Source DB:  PubMed          Journal:  Nefrologia        ISSN: 0211-6995            Impact factor:   2.033


  4 in total

1.  Bioimpedance spectroscopy for fluid status assessment in patients with decompensated liver cirrhosis: Implications for peritoneal dialysis.

Authors:  Elisabeth Schwaiger; Amrei Simon; Peter Wabel; Benjamin Schairer; Carolin Berner; Lorenzo Signorini; Matthäus Ernstbrunner; Rayko Evstatiev; Philipp Schwabl; Georg Hinterholzer; Florian Frommlet; Andreas Vychytil; Christian J Müller; Manfred Hecking
Journal:  Sci Rep       Date:  2020-02-18       Impact factor: 4.379

2.  Overhydration and low serum prealbumin predict peritoneal dialysis-related peritonitis in continuous ambulatory peritoneal dialysis patients.

Authors:  Quyen Dao Bui Quy; Tuan Pham Ngoc Huy; Loc Nguyen Duc; My Pham Van; Dung Nguyen Huu; Toan Nguyen Duy; Tien Tran Viet; Quyet Do; Thang Le Viet
Journal:  BMC Nephrol       Date:  2020-11-25       Impact factor: 2.388

3.  Cost-effectiveness and value of information analysis of multiple frequency bioimpedance devices for fluid management in people with chronic kidney disease having dialysis.

Authors:  Elisabet Jacobsen; Moira Cruickshank; David Cooper; Angharad Marks; Miriam Brazzelli; Graham Scotland
Journal:  Cost Eff Resour Alloc       Date:  2021-04-26

4.  The association between office blood pressure and fluid status using bioimpedance spectroscopy in stable continuous ambulatory peritoneal dialysis patients.

Authors:  Adriaan Slabbert; Mogamat-Yazied Chothia
Journal:  Clin Hypertens       Date:  2022-03-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.